Impulse Biomedical, a Cape Town-based MedTech startup, has secured funding from E Squared Investments and ANZA Capital to commercialise its groundbreaking healthcare devices and expand into global markets. The funding marks a significant milestone in the company’s growth journey as it prepares for a future Series A capital raise. With this investment, the company will also be better positioned to navigate regulatory requirements and scale its operations both locally and internationally.
Revolutionising Emergency Care Through Innovation
Founded by engineering entrepreneurs Giancarlo Beukes and Gokul Nair, Impulse Biomedical is at the forefront of medical device innovation. The company has developed two flagship products aimed at improving emergency care: the Easy Squeezy, a user-friendly asthma inhaler, and the ZiBiPen, the world’s first reloadable epinephrine auto-injector. These inventions not only offer cost-effective alternatives to traditional devices but also address critical accessibility issues for patients in underserved communities.
Investment to Drive Impact-Driven Growth
E Squared Investments, known for supporting scalable ventures that deliver social and economic impact, expressed strong confidence in the startup’s mission. Pyi Maung, Head of Investments at E Squared, stated that Impulse Biomedical exemplifies the kind of purpose-driven entrepreneurship needed both in South Africa and globally. The financial backing is expected to contribute not only to the company's product development but also to job creation, skills training, and inclusive economic transformation.
From Local Roots to Global Reach
Impulse Biomedical’s innovations are already attracting attention for their potential to reshape how emergency care is delivered, particularly in low-resource settings. By offering reloadable and reusable medical devices, the startup is challenging the single-use model that dominates much of the healthcare industry. With the new funding, the team aims to make these life-saving tools available to a global audience, starting with markets that are most in need.
Building on a Track Record of Support
This is not the first time Impulse Biomedical has attracted investor interest. In 2021, the startup received early-stage funding from Futuregrowth, which helped lay the groundwork for its current growth trajectory. The latest investment from E Squared and ANZA Capital signals strong continued belief in the company’s ability to deliver both commercial success and social impact.
Engineering a Healthier Future
Co-founder Giancarlo Beukes emphasised that the partnership marks a crucial turning point in the company’s efforts to make accessible healthcare a reality. He underscored the alignment of values between the startup and its new investors, particularly a shared vision for health equity and global impact. “With a shared passion for impact, progress and a better tomorrow, we are excited to work with E Squared to place our innovations – present and future – in the hands of people around the world,” Beukes said.
Impulse Biomedical stands as a compelling example of how local innovation, when paired with strategic investment, can address global health challenges while uplifting regional economies. As it scales up production and reaches new markets, the company remains committed to creating affordable, sustainable medical technologies that save lives. With the support of mission-aligned investors, Impulse Biomedical is poised to become a global player in the MedTech industry while staying rooted in its commitment to social impact.